FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma
CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.
United States Antonio Chiocca Harvard Medical School Department Of Neurosurgery At Brigham Peter Tak Candel Therapeutics
Source: onclive.com